Janux Therapeutics (JANX) Receivables - Net (2020 - 2026)

Janux Therapeutics (JANX) has 6 years of Receivables - Net data on file, last reported at $35.0 million in Q1 2026.

• On a quarterly basis, Receivables - Net changed N/A year-over-year to $35.0 million in Q1 2026; TTM through Mar 2026 was $35.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $8.0 million, changed N/A from the prior year.
• Receivables - Net for Q1 2026 stood at $35.0 million, up from $7.5 million in the prior quarter.
• Over the last five years, Receivables - Net for JANX reached as high as $35.0 million in Q1 2026 and fell as low as $500000.0 in Q3 2022.
• Historically, Receivables - Net has averaged $8.8 million across 4 years, with a median of $750000.0 in 2023.
• On a YoY basis, Receivables - Net climbed as much as 33.33% in 2024 and fell as far as 33.33% in 2024.
• Year by year, Receivables - Net stood at $500000.0 in 2022, then soared by 50.0% to $750000.0 in 2023, then jumped by 900.0% to $7.5 million in 2024, then soared by 366.67% to $35.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $35.0 million in Q1 2026, $7.5 million in Q2 2024, and $500000.0 in Q1 2024.